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Long-term dietary fatty acid intake is believed to induce changes in the human
gut microbiome which might be associated with human health or obesity status;
however, considerable debate remains regarding the most favorable ratios of fatty
acids to optimize these processes. The objective of this sub-study of a double-blinded
randomized crossover clinical study, the canola oil multi-center intervention trial, was to
investigate effects of five different novel oil blends fed for 30 days each on the intestinal
microbiota in 25 volunteers with risk of metabolic syndrome. The 60 g treatments
included three MUFA-rich diets: (1) conventional canola oil (Canola); (2) DHA-enriched
high oleic canola oil (CanolaDHA); (3) high oleic canola oil (CanolaOleic); and two
PUFA-rich diets: (4) a blend of corn/safflower oil (25:75) (CornSaff); and (5) a blend
of flax/safflower oil (60:40) (FlaxSaff). Stool samples were collected at the end of each
period. DNA was extracted and amplified for 16S rRNA gene pyrosequencing. A total
of 17 phyla and 187 genera were identified. While five novel oil treatments failed to
alter bacterial phyla composition, obese participants resulted in a higher proportion
of Firmicutes to Bacteroidetes than overweight or normal weight groups (P = 0.01).
Similarly at the genus level, overall bacterial distribution was highly associated with
subjects’ body mass index (BMI). Treatment effects were observed between MUFA-
and PUFA-rich diets, with the three MUFA diets elevating Parabacteroides, Prevotella,
Turicibacter, and Enterobacteriaceae’s populations, while the two PUFA-rich diets
favored the higher abundance of Isobaculum. High MUFA content feedings also resulted
in an increase of Parabacteroides and a decrease of Isobaculum in obese, but not
overweight subjects. Data suggest that BMI is a predominant factor in characterization
of human gut microbiota profile, and that MUFA-rich and PUFA-rich diets impact the
composition of gut microbiota at lower taxonomical levels mainly in obese subjects.
Keywords: monounsaturated fatty acid (MUFA), polyunsaturated fatty acid (PUFA), blended oil, gut microbiota,
BMI
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INTRODUCTION
The prevalence of metabolic syndrome (MetS) is dramatically
increasing worldwide (Mente et al., 2009), with major attention
directed on examining effects of dietary fat types, and particularly
the optimal ratio of saturated fatty acid (SFA), monounsaturated
fatty acid (MUFA), and polyunsaturated fatty acid (PUFA). High
amounts of n-6 PUFA, mainly linoleic acid (LA) replacing the
SFA contents found in present Western diets, have been shown
to prevent cardiovascular diseases (Kim et al., 2013). Other types
of PUFA including n-3 PUFA-rich diets also resulted in weight
loss in humans (Madsen et al., 2005). The Mediterranean diet
has long been associated with decreased prevalence of obesity
and diabetes, and increased longevity (Bergouignan et al., 2009),
partly because of the favorable effects of its MUFA content from
olive oil, mainly oleic acid (OA). Therefore, although current
dietary recommendations suggest reductions in intakes of SFA,
they fall short of providing the optimal ratios of unsaturated
fatty acids needed to prevent MetS development. Novel modified
oils, designed as sources of blended MUFA and PUFA contents,
are expected to significantly improve risk factors of MetS,
including central obesity, body mass index (BMI), blood pressure,
impaired glucose tolerance, lipid profile, age and lifestyle (Alberti
et al., 2005). Recent evidence suggest that the composition of
gut microbiota may play a role in metabolism and adiposity,
implicated in MetS risk (Ley, 2010).
Each individual houses a specific and diverse composition
of gut microbiome, which potentially impacts their health.
Differences in the gut microbiota patterns have been observed
between normal weight and obese animals (Ley et al., 2005;
Turnbaugh et al., 2008; Myles et al., 2014). In humans, the gut
microbiota has also been reported to impact the physiological
state of obesity (Turnbaugh et al., 2009a). Although the
links between the composition of gut microbiota and specific
conditions associated with obesity are not clearly understood, an
increased ratio of two dominant bacterial phyla, Firmicutes to
Bacteroidetes appears to associate with obese-type humans and
further correlate to obesity and MetS development (Ley et al.,
2006). Therefore, manipulation of gut microbiome composition
in obese subjects may have potential therapeutic implications for
maintaining human health.
The composition of the gut microbiota can change
dramatically in response to long-term dietary intake as
nutrients obtained through foods are essential to these bacteria.
A recent study comparing the gut microbiota of children
from Burkina Faso and Italy revealed that the ratio of two
dominant phyla, Bacteroidetes and Firmicutes, were entirely
different between the two groups (De Filippo et al., 2010).
Here, differences in dietary patterns presumably contributed to
the shifts in microbiota, which in turn influenced overall host
physiology and metabolism. Studies on traditional Western
diets rich in SFA but low in fiber content demonstrated
that the diets rich in SFA possessed stronger effects than
unsaturated fatty acids in shifting gut microbiota profiles
toward those in obese individuals (de Wit et al., 2012; Liu
et al., 2012). On the other hand, very few studies to date have
investigated the impacts of novel vegetable oils rich in MUFA
or PUFA on the gut microbiota in a longer-term human clinical
trial.
Therefore, the cause-and-effect relationships between any shift
of the gut microbiota, the obese state itself, and the diet remain
unknown (Conterno et al., 2011).
Here, we hypothesized that healthy dietary oil treatments with
diverse fatty acid compositions, particularly those rich in MUFA
or PUFA, may influence the bacterial composition in human
gut. Objectives of present study were to investigate (1) whether
significant differences in the gut microbiota composition (as
represented by the feces Krause and Khafipour, 2011) could be
produced in response to MUFA or PUFA oil blends; (2) how
the obese status influences the gut bacterial communities during
the interventions; and (3) whether the change in gut microbiota
composition is correlated with the change in biomarkers of
MetS.
MATERIALS AND METHODS
Clinical Design
The Canola Oil Multi-center Intervention Trial (COMIT)
was conducted at Richardson Centre for Functional Foods
and Nutraceuticals (RCFFN) at University of Manitoba, the
Institute of Nutraceuticals and Functional Foods (INAF) at
Laval University, and the Department of Nutritional Sciences at
Pennsylvania State University (PSU) between September 2010
and March 2012. The intervention studies were reviewed and
approved by institutional ethics boards in respective participating
universities. Written consents were obtained from all subjects
as prescribed by Research Ethics Boards at all clinical centers.
The protocol of the present sub-study of COMIT was approved
by Biomedical Research Ethics Board (BREB) at University of
Manitoba. The clinical trial was registered with clinicaltrials.gov
(NCT01351012).
The COMIT study was designed as a random, controlled,
double-blind, crossover clinical trial on volunteers at risk of MetS,
as previously described (Senanayake et al., 2014). Adult men
and women with at least one of the following cardiovascular
risk factors were recruited for the study: waist circumference
≥94 cm for men and ≥80 cm for women, triglyceride (TG):
≥ 1.7 mmol/L, HDL cholesterol (HDL-C): <1 mmol/L (men) or
<1.3 mmol/L (women), blood pressure: ≥130 mmHg (systolic)
and/or ≥ 85 mmHg (diastolic) and glucose: ≥ 5.5 mmol/L.
Participants with thyroid disease, diabetes mellitus, kidney
disease, liver disease, current smokers, or people drinking
more than two alcoholic beverages per week were excluded
from the study. During the trial, volunteers who took any
medication known to affect endothelial function during the
trial were released from protocol, but those who were taking
blood pressure medication with a constant dose were included.
All participants provided written consent before clinical trial
started. The endpoint data for serum lipid variables [Total
Cholesterol (TC), HDL-C, LDL Cholesterol (LDL-C), TG] for
the 25 subjects included in the microbiome study were extracted
from previously reported COMIT data (Jones et al., 2014),
reanalyzed (Supplementary Figure S7) and reinterpreted in the
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TABLE 1 | Fatty acid composition of five dietary oil treatments1 (g) consumed at 60 g/d (35% of energy intake based on 3000 kcal/d).
Fatty acids Canola CanolaDHA CanolaOleic CornSaff FlaxSaff
g (% of energy)
SFA2
C12:0 0.05 0.04 0.04 0.00 0.00
C14:0 0.04 0.47 0.04 0.00 0.00
C16:0 2.44 3.15 2.20 3.52 2.94
C17:0 0.04 0.10 0.05 0.01 0.00
C18:0 1.10 1.02 1.10 1.14 1.90
C20:0 0.39 0.34 0.39 0.06 0.00
C22:0 0.19 0.18 0.19 0.00 0.00
C24:0 0.11 0.09 0.11 0.00 0.00
Total SFA 4.36 (6.6) 5.39 (6.9) 4.12 (6.5) 4.73 (6.7) 4.84 (6.8)
MUFA3
C16:1 0.15 0.12 0.13 0.02 0.00
C17:1 0.07 0.10 0.12 0.00 0.00
C18:1 35.17 37.95 42.88 10.56 10.72
C20:1 0.73 0.62 0.72 0.02 0.00
C22:1 0.03 0.04 0.04 0.00 0.00
Total MUFA 36.15 (17.6) 38.84 (17.8) 43.89 (19.3) 10.60 (9.5) 10.72 (9.6)
PUFA4
C18:2 11.72 7.65 8.84 41.61 22.48
C18:3 5.86 1.18 1.38 0.17 19.19
C20:4 0.00 0.04 0.00 0.00 0.00
C20:5 0.00 0.09 0.00 0.00 0.00
C22:5 0.00 1.42 0.00 0.00 0.00
C22:6, 0.00 3.48 0.00 0.00 0.00
Total PUFA 17.58 (9.1) 13.86 (8.0) 10.22 (6.9) 41.78 (16.3) 41.67 (16.3)
1Dietary oil treatments are Canola, conventional canola oil; CanolaDHA, high oleic canola oil with DHA (85:15); CanolaOleic, high oleic canola oil; CornSaff, corn oil and
safflower oil blend (25:75); FlaxSaff, flax oil and safflower oil blend (60:40). 2,3,4SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty
acid.
context of their correlations with microbial changes evaluated in
this research.
The five-phase randomized full-feeding study design provided
subjects with a consistent, individual weight-maintaining diet
with a fixed 7-day rotation isocaloric menu of three meals and
two snacks a day, including 50% carbohydrate, 15% protein
and 35% fat of total energy of 3000 Kcal per day. A daily
intake of 60 g dietary oils was equally distributed to two
identical sizes of beverage shakes at breakfast and supper. Five
oil treatments included: (1) canola oil [Canola; 63% MUFA, 20%
LA, 10% α-linolenic acid (ALA)]; (2) DHA enriched canola-oil
[CanolaDHA; 64% MUFA, 13% LA, 6% docosahexaenoic acid
(DHA)]; (3) high OA canola oil (CanolaOleic; 72% MUFA, 15%
LA, 2% ALA); (4) a blend of corn oil/saﬄower oil (CornSaff; 18%
MUFA, 69% LA); and (5) a blend of flax oil/saﬄower oil (FlaxSaff;
18% MUFA, 38% LA, 32% ALA) (Table 1). All five diets were
low in SFA, and SFA was replaced with different combinations
of unsaturated fatty acids. Three canola-based diets were rich in
MUFA while two saﬄower oil blends were high in n-3 PUFA or
n-6 PUFA. To compare the impacts of MUFA-rich diets (Canola,
CanolaDHA, and CanolaOleic) with those of PUFA-rich diets
(CornSaff and FlaxSaff) on the gut microbiota, a contrast analysis
was performed. Comparisons of subgroups between CanolaDHA
and CanolaOleic, and CornSaff and FlaxSaff were also conducted.
All the meals and shakes were prepared fresh in the metabolic
kitchen. Participants were instructed to visit the research site
and consume at least one meal containing one dose of treatment
beverage (usually breakfast) under the supervision of the clinical
staff in the cafeteria on weekdays, while the remaining meals and
weekend proportions were packed for off-site consumption. No
outside food was allowed to consume during the intervention
period. Compliance was assessed by clinical staff by the rate of
completion of meals provided under supervision as well as by
the presence of food not consumed in their returned meal bags
packed for off-site consumption. Both participants and study
coordinators were blinded to the treatments. Each treatment
phase lasted 30 days in duration and separated with 4 weeks
washout periods.
Stool Collection
Twenty-five participants from RCFFN (Winnipeg, MB, Canada)
arm of the COMIT trial agreed to provide 5 g stool samples
at the end of each intervention phase for the present study
(Supplementary Tables S1 and S2). Subjects were instructed to
collect their own samples from only one bowel movement in
the privacy of their home the day before they visited RCFFN on
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either day 29 or day 30 of their endpoint visits. Subjects were
directed to store fecal specimens immediately after collection at
−20◦C freezer until collector tubes were handed over to clinical
coordinators at RCFFN. Fecal specimens subsequently labeled
and stored at−80◦C until further analysis.
DNA Extraction
The frozen fecal specimens in collector tubes were wrapped
in individual zipper bags and placed in a cooler with ice
packs at RCFFN. After transport to the Gut Microbiome and
Large Animal Biosecurity Laboratories at Department of Animal
Science, University of Manitoba, fecal samples were thoroughly
thawed and homogenized at room temperature. Genomic DNA
was then extracted from approximately 250 mg fecal mass using
ZR Fecal DNA Kit (D6010, Zymo Research Corp., Orange, CA,
USA), which included a bead-beating step to lyse microbial
cells, according to the manufacturer’s protocol. To match the
concentration requirement for pyrosequencing, DNA quantity
was determined under a Beckman DU/800 spectrophotometer
(Beckman Coulter, Inc., Fullerton, CA, USA). Genomic DNA
was normalized to achieve a concentration of 20 ng/µL and
quality checked by PCR amplification of the 16S ribosomal
RNA (rRNA) gene, 27f (5′-GAAGAGTTTGATCATGGCTCAG-
3′) and 342r (5′-CTGCTGCCTCCCGTAG-3′) (Sepehri et al.,
2007; Khafipour et al., 2009). Amplicons were verified by agarose
gel electrophoresis.
Pyrosequencing
Approximately 200 ng aliquots of high quality, inhibitor-
free genomic DNA were sent to the Research and Testing
Laboratories (Lubbock, TX, USA) for bacterial rRNA gene tag-
encoded GS FLX-Titanium amplicon pyrosequencing (Dowd
et al., 2008). Briefly, a mixture of Hot Start, HotStar high-
fidelity Taq polymerases, and Titanium reagents were used
to perform a one-step PCR (35 cycles). Pyrosequencing was
performed using a 454 GS FLX-Titanium Sequencing System
(454 Life Sciences, Roche Company, Branford, CT, USA).
The primers 28f (GAGTTTGATCMTGGCTCAG) and 519r
(GTNTTACNGCGGCKGCTG) were utilized to target the
variable regions V1–V3 of the bacterial 16S rRNA genes.
The sequencing data are uploaded into the Sequence Read
Archive of NCBI1 and are accessible through accession number
SRR2959981.
Sequence Classification and Diversity
Analysis
Sequencing data, which are categorical data, were edited,
transformed and classified as described previously (Li et al.,
2012). In general, all failed sequence reads, low-quality sequence
ends, tags, and non-bacterial ribosome sequences and chimeras
were removed from the dataset. Using software mothur (version
1.30.2) (Schloss et al., 2009), the second round of sequence
quality control and assignments of operational taxonomic unit
(OTU) were performed. All sequences less than 200 bp or
1http://www.ncbi.nlm.nih.gov/sra
sequences having one or more ambiguous base or containing a
homopolymer length more than 8 bp were excluded from the data
set. High quality 16S rRNA gene sequences were identified and
aligned using the comprehensive rRNA database Silva (Pruesse
et al., 2007) to reduce the noise from pyrosequencing data. The
remaining sequence position columns and sequences were used
to build a distance matrix with a distance threshold of 0.15. Using
the furthest neighbor algorithm with a cutoff of 95% similarity,
these sequences were clustered to OTU.
Within community diversity (α-diversity) was conducted
based on OTU counts to evaluate the biodiversity of the bacterial
population in the fecal samples at the genus level. Richness
indices, Chao1 and abundance based coverage estimation (ACE),
Shannon index and Simpson diversity were calculated to estimate
the number of OTU that were present in each individual
sample. Appropriate statistical considerations were used to
exclude samples with extremely high or low diversity as outliers.
A rarefaction curves, which allows the calculation of sequence
richness, were also performed for five treatment groups and BMI
groups using mothur (Schloss et al., 2009) based on randomly
re-sampling the pool of sequence numbers.
To evaluate the differences in community composition
among different treatments and BMI populations, β-diversity
was measured by calculating the Bray-Curtis distance (Clarke
et al., 2006). Principal coordinate analysis (PCoA) was applied
on resulting distance matrices to generate two-dimensional
plots using PRIMER v6 software (Warwick and Clarke, 2006).
Permutational multivariate analysis of variance (PERMANOVA)
was performed to assess significant differences of β-diversity
among the treatments and BMI groups on the basis of distance
measures using permutation methods (Anderson, 2005).
Statistical Analysis
Based on the outcomes from mothur, the phyla and genera
in relatively low abundance (under 0.1% of community) were
removed from further analysis. SAS version 9.2 (SAS Institute
Inc., Cary, NC, USA) was used for data analysis. Normality
of residuals for α-diversity indices was tested by Kolmogorov–
Smirnov tests and histograms were used to test the Gaussian
nature of the dataset. The significance of differences between
treatments was analyzed using mixed model with treatment
followed by Tukey adjustment.
Normal distribution was tested by Kolmogorov–Smirnov tests
and histograms, and Box-Cox power transformation macro was
used if necessary when analyzing statistical differences among
treatments or contrasts at phylum and genus levels. Depending
on the distribution of the residuals, MIXED or GLIMMIX models
in SAS with mixed-effect analysis of variance with treatment
as fixed effect, and subject as a random effect followed by
Tukey adjustment, were conducted to estimate the significant
differences. Differences between treatments were considered
significant at P < 0.05 while trends were observed at P < 0.1.
The non-parametric Spearman correlation matrix was
generated and Spearman’s ρ and P-values were calculated to
investigate the correlations between fecal microbiome and
serum lipid profiles using the PAST software (PAleontological
Statistics; Hammer et al., 2001). The results were visualized over
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heatmap using core plot package of R (R Core Team, 2013).
Taxa with relative abundance greater than 0.1% of community
were included in the analysis. Strong and weak correlations were
presented by dark and light colors, respectively. The Spearman’s
Rho denotes whether the correlation between the taxa of interest
and the selected parameter was positive (closer to 1, blue squares)
or negative (closer to−1, red squares).
Partial least square discriminant analysis (PLS-DA) was
performed on bacterial genera to identify the effects of dietary
oil treatments on the bacterial community, according to our
previously described analytical method with modifications (Li
et al., 2012). For this analysis, data were scaled using Unit
Variance in SIMCA-P+ 13.0 (Umetrics, Umea, Sweden). Cross-
validation and permutation testing were conducted to determine
significant PLS components in the optimal model. To avoid over
parameterization of the model, a cut-off level was set for variable
influence on projection (VIP) value in each model to improve
R2 and Q2 with better prediction of the bacterial distribution.
Significant differences across treatments or BMI groups were
expressed in scatter and score plots, according to the PLS
regression coefficients. Each individual genus 95% confidence
interval determined the positive or negative correlations with
dietary treatments or BMI groups.
RESULTS
Sample Assessment by Pyrosequencing
After the 5-phase clinical trial, a total of 66 samples were collected
from 25 subjects. Missing samples resulted from participants
either forgetting to collect samples or failing to provide samples
at expected sampling dates (Supplementary Table S1). In total,
209,490 sequences were first generated. The minimum, median
and maximum lengths of sequences were 250, 393, and 698 bp,
respectively. Screening, filtering, and pre-clustering processes
resulted in 142,887 sequences.
Alpha and β-Diversity Analyses
Bacterial richness and diversity in individual samples under
different oil treatments and BMI were calculated (Table 2). Oil
treatments and BMI had no significant impact on Chao1, ACE,
Shannon and Simpson indices of α-diversity (Figure 1A and
Table 2). However, the rarefaction curves showed higher richness
and diversity in overweight and obese subjects compared to the
normal weight participants (Figure 1B). Similarity or differences
in the gut microbiota among different oil treatments and BMI
(β-diversity) were compared using PCoA and PERMANOVA
analyses of Bray-Curtis distances (Supplementary Figures S1–
S6). Comparisons included MUFA vs. PUFA (P = 0.84), normal
weight vs. overweight (P = 0.11), normal weight vs. obese
(P < 0.01), overweight vs. obese (P = 0.03), MUFA vs. PUFA
within overweight group (P= 0.57), and MUFA vs. PUFA within
obese group (P = 0.99). The β-diversity did not change among
individual oil treatments.
Overall Gut Microbiota Composition
A total of 15 phyla were identified in all the samples from
99.8% of all sequences (Supplementary Table S3), of which four
phyla were considered as abundant within the community (larger
than 1%), including Firmicutes, Bacteroidetes, Actinobacteria,
and Proteobacteria (Table 3). The abundance of Aquificae,
Fusobacteria, and Verrucomicrobia were between 0.1 and 1%
TABLE 2 | Summary statistics for sequences using 16S rRNA gene pyrosequencing.
Variables2 Mean results for indicated variables1
Sequence Number OTU Number3 Coverage (%) Richness4 Diversity5
Chao 1 ACE Shannon Simpson
Treatments
Canola 2521 121 98.38 173.86 218.10 3.17 0.11
CanolaDHA 2497 112 98.98 126.19 129.81 3.47 0.07
CanolaOleic 2486 116 98.46 162.87 201.23 3.23 0.09
CornSaff 2174 139 97.63 232.30 296.89 3.43 0.08
FlaxSaff 2414 111 98.37 149.42 181.24 3.28 0.11
SEM 14.78 0.26 13.67 46.67 0.15 0.02
P-value 0.69 0.01 0.15 0.15 0.53 0.58
BMI groups
Normal 2401 121 98.50 150.15 162.20 3.46 0.07
Overweight 2673 134 98.30 186.84 224.48 3.37 0.09
Obese 2277 111 98.39 164.07 206.67 3.24 0.09
SEM 12.41 0.25 26.72 41.11 0.13 0.02
P-value 0.27 0.88 0.65 0.66 0.49 0.71
1Means are from statistical models based on 66 fecal samples across five treatments. 2Dietary oil treatments are Canola, conventional canola oil; CanolaDHA, high oleic
canola oil with DHA (85:15); CanolaOleic, high oleic canola oil; CornSaff, corn oil and safflower oil blend (25:75); FlaxSaff, flax oil and safflower oil blend (60:40). BMI
groups are normal, overweight, and obese subjects. 3OTU, operational taxonomic units. 4Based on Chao1 and abundance based coverage estimation (ACE) richness
indices. 5Based on Shannon and Simpson diversity estimators.
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FIGURE 1 | (A,B) Rarefaction analysis for the observed species. The rarefaction curve is generated using Chao1 richness estimator according to oil treatments (A)
or subjects’ body mass index (BMI; B). Samples have been rarified at an even depth of 21,000 sequences per oil treatment or BMI group.
of community. The remaining eight phyla, which were in low
abundance (under 0.1%) included Acidobacteria, Chrysiogenetes,
Cyanobacteria, Deinococcus-Thermus, Nitrospira, Synergistetes,
TM7, and Tenericutes. Overall, the phylum distribution did not
fluctuate across the five oil treatments or among MUFA vs. PUFA
groups. However, BMI status had an impact on the microbiota
composition at the phylum level with obese group having greater
proportion of Firmicutes (P = 0.02) compared to the combined
group of normal and overweight subjects (data not shown). The
average ratio of Bacteroidetes to Firmicutes was 0.15 across five
diets with no difference among dietary interventions (data not
shown).
At the genus level, 187 genera were determined using
16S rRNA gene pyrosequencing. Majority of sequences were
identified at the genus (g.) level while some sequences could
only be classified up to phylum (p.), class (c.), order (o.), or
family (f.) levels. Supplementary Tables S4 and S5 present the
distribution of taxa with a relative abundance >0.1% and <0.1%
of community, respectively, among diets. The abundance of g.
Faecalibacterium tended to differ across treatments (P = 0.06)
where CanolaOleic feeding was associated with the highest
level of Faecalibacterium and CanoalDHA feeding with the
lowest level. Data also showed a tendency for higher proportion
of g. Parabacteroides (P = 0.09) but lower proportion of
g. Isobaculum (P = 0.08) when the three MUFA-rich diets
compared to two PUFA-rich diets. Genus Blautia was observed
to favor the CanolaOleic feeding compared to the CanolaDHA
diet (P = 0.09). No differences were observed between n-
6 PUFA-rich treatment CornSaff and n-3 PUFA-rich diet
FlaxSaff.
TABLE 3 | Relative abundances of bacterial phyla from 16S rRNA gene sequences.
Phyla Percentages of sequences in treatments1 Mean2 SEM P-value3 Contrasts (P-value)4
Canola CanolaDHA CanolaOleic CornSaff FlaxSaff MUFA/ CanolaDHA/ CornSaff/
PUFA CanolaOleic FlaxSaff
Above 1% of community
Actinobacteria 2.85 3.23 2.75 2.92 1.97 2.80 0.16 0.28 0.32 0.88 0.38
Bacteroidetes 11.60 11.77 12.81 10.90 10.77 11.62 0.71 0.83 0.51 1.00 0.85
Firmicutes 82.37 82.23 80.60 83.08 85.18 82.51 0.81 0.75 0.21 1.00 0.98
Proteobacteria 1.96 1.42 2.24 1.65 1.22 1.74 0.23 0.68 0.17 0.83 0.99
Between 0.1 and 1% of community
Aquificae 0.58 0.63 0.56 0.82 0.26 0.59 0.12 0.79 1.00 0.99 0.81
Fusobacteria 0.26 0.25 0.38 ∗ 0.18 0.22 0.08 0.68 0.91 1.00 N/A
Verrucomicrobia 0.19 0.16 0.26 0.13 0.24 0.19 0.05 0.95 0.84 0.98 0.98
1Dietary oil treatments are Canola, conventional canola oil; CanolaDHA, high oleic canola oil with DHA (85:15); CanolaOleic, high oleic canola oil; CornSaff, corn oil and
safflower oil blend (25:75); FlaxSaff, flax oil and safflower oil blend (60:40). 2Means for each phylum under five treatments are individually reported. The Mean and SEM
are also reported across five treatments. 3P-values adjusted by Tukey are significantly different at P < 0.05. 4The contrast of different treatment groups or comparison
between selected treatment groups. MUFA/PUFA is the contrast of the combination of Canola, CanolaDHA, and CanolaOleic compared to the combination of FlaxSaff
and CornSaff. CanolaDHA/CanolaOleic is the comparison between CanolaDHA and CanolaOleic. CornSaff/FlaxSaff is the comparison between CornSaff and FlaxSaff.
P-values adjusted by Tukey are significantly different at P < 0.05. ∗Percentage of sequences below 0.1.
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FIGURE 2 | Partial least square discriminant analysis (PLS-DA) loading plot based on the relative abundances of bacterial genera in the gut
microbiota and their association with MUFA-rich or PUFA-rich diets. The presenting genera are chosen at VIP cutoff of 1.0 and colored according to their
corresponding phyla. The size of circles is indicative of taxa abundance. Taxa closer to MUFA or PUFA indicate positive association with either treatment group. The
R2 (=0.43) and Q2 (=0.07) estimates were calculated based on three components. While majority of sequences were identified at the genus level (G), some could
only be affiliated to phylum (P), class (C), order (O), or family (F) levels.
The PLS-DA analysis (given for the cutoff value of
1.0) showed further differences at the lower taxonomical
levels. Genera Parabacteroides, Prevotella, Turicibacter, and
f. Enterobacteriaceae were correlated to MUFA-rich diets, while
g. Isobaculum was correlated to PUFA-rich diets (R2 = 0.43,
Q2 = 0.07; Figure 2). Comparison between CanolaDHA and
CanolaOleic indicated that CanolaDHA was correlated to f.
Lachnospiraceae and p. Firmicutes, whereas CanolaOleic was
associated with g. Faecalibacterium and Coprobacillus (R2 = 0.78,
Q2 = 0.45; Figure 3). The comparison between two PUFA-
rich diets showed CornSaff treatment had an impact on the
populations of g. Eggerthella, Slackia, Soehngenia, Anaerostipes,
Robinsoniella, Phascolarctobacterium, while FlaxSaff failed to
have such significant impact (R2 = 0.67, Q2 = 0.22; data not
shown).
Gut Microbiota Profiles Within Individual
Obese Status
At the phylum level, a significantly higher proportion of
Firmicutes was observed in obese group (BMI > 30) compared
to the combined group of normal weight (BMI < 25) and
overweight subjects (BMI between 25 and 30; P = 0.02; data
not shown). At the genus level, PLS-DA analysis confirmed
a significant difference in the composition of bacteria among
three BMI phenotype groups (R2 = 0.60, Q2 = 0.32;
Figure 4).
Since the number of subjects in the normal weight category
was insufficient, the analysis on contrasts and subgroups
only focused on two representative populations, overweight
and obese groups. In overweight people, g. Streptococcus,
Tepidimicrobium, Robinsoniella, and Turicibacter were correlated
to MUFA-rich diets, while g. Coriobacterium and Mogibacterium
were associated with PUFA-rich diets (R2 = 0.69, Q2 = 0.26;
Figure 5). In the comparison between CanolaDHA and
CanolaOleic, g. Adlercreutizia, Coriobacterium, Alistipes, and
Robinsoniella showed strong correlations with CanolaDHA while
g. Lactobacillus was associated with CanolaOleic (R2 = 0.90,
Q2 = 0.60; data not shown). In the comparison between
the two PUFA-rich diets, CornSaff was highly associated
with g. Adlercreutizia while FlaxSaff was correlated with g.
Collinsella, Barnesiella, Streptococcus, Roseburia, Coprobacillus,
and family Peptostreptococcaceae (R2 = 0.98, Q2 = 0.74; data not
shown).
In obese subjects, g. Parabacteroides, Prevotella, Flexithrix,
Fusibacter, f. Enterobacteriaceae, and p. Firmicutes were
correlated to MUFA-rich diets, but no specific taxa was
associated with PUFA-rich diets (R2 = 0.66, Q2 = −0.20;
Figure 6). In comparison of CanolaDHA and CanolaOleic,
only g. Parasutterlla correlated with CanolaDHA (R2 = 0.91,
Q2 = 0.29; data not shown). Between the two PUFA-rich
diets, g. Collinsella, Hydrogenobaculum, and Parabacteroides
were impacted by the CornSaff, while g. Clostridium was
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FIGURE 3 | Partial least square discriminant analysis loading plot based on the relative abundances of bacterial genera in the gut microbiota and
their association with CanolaDHA or CanolaOleic diets. The presenting genera are chosen at VIP cutoff of 1.0 and colored according to their corresponding
phyla. The size of circles is indicative of taxa abundance. Taxa closer to CanolaDHA or CanolaOleic diets indicate positive association with either treatment group.
The R2 (=0.78) and Q2 (=0.45) estimates were calculated based on three components. While majority of sequences were identified at the genus level (G), some
could only be affiliated to phylum (P), class (C), order (O), or family (F) levels.
correlated to the FlaxSaff diet (R2 = 0.98, Q2 = 0.63; data not
shown).
Correlations between Serum Lipid
Variables and Gut Microbiota Profiles
The endpoint data for serum lipid variables of the 25 subjects
included in this sub-study were extracted from previously
reported COMIT data (Jones et al., 2014) and reanalyzed.
All changes in lipid profiles followed the same trends of
the entire study population (Supplementary Figure S7).
The correlations between lipid profiles and bacterial
phyla are presented in Supplementary Table S6. Across
treatments, serum TG was negatively correlated with Aquificae
(Spearman’s ρ = −0.27, P = 0.02) but positively correlated
with Cyanobacteria (Spearman’s ρ = 0.24, P = 0.05). In
contrast, LDL-C was positively correlated with p. Proteobacteria
(Spearman’s ρ = 0.28, P = 0.01) and similar tendency was
observed for TC (Spearman’s ρ = 0.21, P = 0.08). HDL-C,
however, was positively correlated with Verrucomicrobia
(Spearman’s ρ = 0.21, P = 0.08). In CanolaDHA treatment,
TC levels trended to negatively correlate with Bacteroidetes
(Spearman’s ρ = −0.51, P = 0.06) and positively correlated
with Firmicutes (Spearman’s ρ = 0.55, P = 0.04), resulting
in negative correlation trend with the ratio of Bacteroidetes
to Firmicutes (Spearman’s Rho = −0.51, P = 0.06). In
CornSaff treatment, TC levels were positively correlated with
Bacteroidetes (Spearman’s ρ = 0.64, P = 0.02) and Bacteroidetes
to Firmicutes ratio (Spearman’s ρ = −0.65, P = 0.02). The
correlations between serum lipid variables and bacterial
composition at the lower taxonomical levels are presented in
Figure 7.
DISCUSSION
We investigated the impact of five different healthy unsaturated
fatty acid oil treatments with a dietary fat content of less than
35% of energy intake on gut microbiota profiles of volunteers
with risks of MetS. Our experimental diets included three MUFA-
rich (Canola, CanolaDHA, and CanolaOleic) and two PUFA-rich
(CornSaff and FlaxSaff) diets and were designed to maintain the
body weight during the treatment periods. Major findings on
post-treatment outcomes indicate that diet, metabolic profiles,
obesity state, and individual responses are all contributing
at different degrees to the shifts in the gut microbiota
compositions. Overall, the impact of our healthy unsaturated
fatty acid oil treatments on the microbiota composition was
relatively minor at the phylum level and mainly associated
with microbiota shifts at the lower taxonomical levels, whereas
BMI contributed to a significant shift at the phylum level
with greater Firmicutes and less Bacteroidetes in obese group
compared to the combined group of normal and overweight
subjects.
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FIGURE 4 | Partial least square discriminant analysis score scatter plot of the gut microbiota comparing subjects with different body mass index
(BMI). The distribution of fecal samples (n = 66) indicated a significant difference in the composition of bacterial genera among obese (BMI > 30), overweight (BMI
between 25 and 30), and normal weight (BMI < 25) groups. The R2 (=0.60) and Q2 (=0.32) estimates were calculated based on three components.
Several studies have investigated the effects of high fat diets
mainly from SFA on the gut microbiota composition [8, 11,
14, 30, 31, 32]. Turnbaugh et al. (2008) showed that diet-
induced obesity can quickly develop with altered microbiota
profiles in mice fed prototypic Western diets with high SFA
content. In a study comparing different types of high fat diets
on the profile of gut bacteria in a mouse model, Liu et al.
(2012) observed that consumption of a SFA-rich diet resulted
in a significant decrease in the abundance of p. Bacteroidetes
compared to either n-3 PUFA-rich or n-6 PUFA-rich diets.
Similarly, a clinical study by Ley et al. (2006) described that
the relative proportion of p. Bacteroidetes decreased in obese
people compared with lean subjects, and this proportion also
increased when the obese individual lost weight due to either
carbohydrate-restricted or fat-restricted diets. Nielsen et al.
(2007) reported that supplementation of fish oil for 1 month in
human infants influenced the intestinal microbiota composition
suggesting that dietary n-3 fatty acids may influence the bacterial
adhesion to the intestinal mucosa, which in turn associates to the
immune response and fat accumulation. Furthermore, Andersen
et al. (2011) reported a significant increase in p. Bacteroidetes
following the n-6 PUFA treatment. In the present study we did
not have a control low fat or a control high fat treatment and the
proportion of dietary fat content in all five treatments was less
than 35% of total energy intake, which is the recommended level
of fat intake in North America to maintain body weight (Grundy
et al., 2002). As a result, our treatments were not considered high
fat diet and we did not expect to see major shifts at the phylum
level in the bacterial composition among n-3 PUFA (FlaxSaff), n-
6 PUFA (CornSaff) and DHA-rich (CanolaDHA) treatments, or
the combination of MUFA-rich vs. PUFA-rich diets. As expected
the differences observed were at the lower taxonomical levels,
for example MUFA-rich diets increased the populations of g.
Prevotella and Parabacteroides within p. Bacteroidetes, and their
impact was more pronounced in the obese people compared to
normal and overweight subjects.
The individuals’ BMI has a major impact on gut microbiota.
A study by Ley et al. (2005) used obese mice with ob/ob,
lean ob/+, and wild-type siblings, and their ob/+ mothers to
investigate the impact of obese genotypes and phenotypes on
the gut microbiota. Results from a 16S rRNA gene sequence
observation showed that ob/ob mice had a decreased abundance
of Bacteroidetes and an increased proportion of Firmicutes.
Authors also reported that the ratio of Bacteroidetes to Firmicutes
dynamically reflects the overall weight condition in mice model.
A follow-up study to extend these observations to humans
showed that the relative proportion of Bacteroidetes is reduced
in obese participants compared to the lean controls (Ley et al.,
2006). However, it is very unlikely that the compositional shifts
in Firmicutes to Bacteroidetes ratio can be solely responsible
for development of obese phenotype. Other researchers, for
example (Schwiertz et al., 2010), have failed to find similar
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FIGURE 5 | Partial least square discriminant analysis loading plot based on the relative abundances of bacterial genera in the gut microbiota and
their association with MUFA-rich or PUFA-rich diets in overweight population (BMI between 25 and 30). The presenting genera are chosen at VIP cutoff of
1.0 and colored according to their corresponding phyla. The size of circles is indicative of taxa abundance. Taxa closer to MUFA or PUFA indicate positive
association with either treatment group. The R2 (=0.69) and Q2 (=0.26) estimates were calculated based on three components. While majority of sequences were
identified at the genus level (G), some could only be affiliated to phylum (P) class (C), order (O), or family (F) levels.
trends when comparing the Firmicutes to Bacteroidetes ratio
between the microbiota of obese and lean individuals, suggesting
that the relationship between MetS, obesity, nutrition, and the
microbiota is complex and multifactorial. Bacteroidetes genomes
have a significantly higher level of functional diversity and, as
demonstrated by the oft-cited study conducted by Turnbaugh
et al. (2009a), the gut microbiome of human subjects from
obese phenotype is functionally less diverse compared to the
Bacteroidetes-rich gut microbiota of lean subjects. In the latter
study, the majority of genes that were discriminating between
the two phenotypes were annotated to carbohydrate, lipid and
amino-acid metabolism pathways, with 75% of the obesity-
enriched genes belonging to Actinobacteria and 42% of the lean-
enriched genes to Bacteroidetes. These shifts in the functional
properties of microbiota can change the energy harvesting
capacities of the host via different mechanisms, for example,
by altering the amount and profile of microbiota-derived short
chain fatty acids (SCFAs), and/or, by modulating the expression
of host genes that affect energy deposition in adipocytes (Bäckhed
et al., 2007; Murphy et al., 2010). In the present study, subjects’
recruitment was based on the presence of at least one of the
MetS risk factors including waist circumference, blood pressure,
TG, HDL-C, and glucose levels. As a result, we didn’t have a
balanced number of subjects at different BMI groups, and thus,
we only observed a tendency of higher ratio of Bacteroidetes
to Firmicutes in normal and overweight people compared to
that of obese subjects. Nevertheless, when the obese states
were classified as subgroups, the correlation coefficients were
significantly improved indicating higher predictability of our
models for detection of microbiota pattern in response to MUFA-
or PUFA-rich diets.
Comparing the MUFA- and PUFA-rich diets, one interesting
finding was the shift in g. Parabacteroides and Isobaculum
populations suggesting that additional dietary OA can result in
an increase in the population of Parabacteroides and a decrease
in Isobaculum. When we chose the overweight and obese groups
for subgroup analysis, contrasting MUFA vs. PUFA, a positive
correlation between Parabacteroides and MUFA-rich diets was
found to exist only in obese but not in overweight subjects.
Further analysis comparing across CanolaOleic and CornSaff or
FlaxSaff oil phases also showed consistent outcomes that this
potential correlation with Parabacteroides was significant but was
only observed in obese but not overweight volunteers. Thus, our
study indicated that the MUFA-rich diets (high OA contents) can
increase the population of Parabacteroides in human gut, and
people with obese status may express a stronger response to such
shift. Unfortunately, there is not much known about the function
of Parabacteroides and Isobaculum and further investigation on
the potential roles of these genera in development of obesity is
needed.
Our results showed that g. Faecalibacterium population was
higher in CanolaOleic treatment compared to CanolaDHA.
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FIGURE 6 | Partial least square discriminant analysis (PLS-DA) loading plot based on the relative abundances of bacterial genera in the gut
microbiota and their association with MUFA-rich or PUFA-rich diets in obese population (BMI > 30). The presenting genera are chosen at VIP cutoff of 1.0
and colored according to their corresponding phyla. The size of circles is indicative of taxa abundance. Taxa closer to MUFA or PUFA indicate positive association
with either treatment group. The R2 (=0.66) and Q2 (=−0.20) estimates were calculated based on three components. While majority of sequences were identified at
the genus level (G), some could only be affiliated to phylum (P) class (C), order (O), or family (F) levels.
Among different species of g. Faecalibacterium, F. prausnitzii
is considered as an indicator of intestinal health due to its
anti-inflammatory effects (Carlsson et al., 2013). Based on our
findings, we can, therefore, hypothesize that additional intake
of OA may increase the anti-inflammatory properties in human
intestines by increasing the population of F. prausnitzii although
further investigation is required.
The gut microbiome profile in humans is host-specific. Fecal
communities in the human gut can change dramatically in
response to new diets. Recent studies have shown that gut
microbiome can rapidly and reproducibly respond to short-term
dietary changes (David et al., 2014). These studies suggest that the
human gut microbiome can rapidly switch between herbivorous
and carnivorous functional profiles, which might be reflective of
past selective pressures during human evolution (David et al.,
2014). Turnbaugh et al. (2009b) using a humanized mice model
showed that switching from a low-fat, plant polysaccharide-
rich diet to a high-fat/high-sugar “Western” diet shifted the
structure of the microbiota within a single day, changed the
representation of metabolic pathways in the microbiome, and
altered microbiome gene expression. The authors also indicated
that the gut microbiota composition was stabilized 7 days
following the dietary switch. As such, the 4-week dietary
interventions used in this study should have been sufficient to
stabilize diet-induced changes in the microbiota. It is clear now
that each individual is relatively unique in terms of bacterial
species of microbiota in their gut, no matter what obese state the
individual belongs to, or what dietary oil treatments are provided.
This may partly explain the variations in the microbiota profiles
among the participants of our study and the variations in their
responses to the dietary treatments.
Evidence showed dietary DHA oil intends to increase LDL-
C levels in humans (Theobald et al., 2004; Jacobson et al.,
2012), although the reason remains unclear. We observed
similar elevated LDL-C levels after CanolaDHA treatment in
the present study, which was significantly correlated with
the increase in Firmicutes and the decrease in Bacteroidetes
within this treatment. These observations are supported by
a mouse study (Mujico et al., 2013), which reported that
a diet supplemented with n-3 fatty acids (Eicosapentaenoic
acid+DHA) significantly increased the abundance of Firmicutes
and reduced the percentage of Bacteroidetes compared to a diet
supplemented with OA. It can be speculated that the changes in
metabolic parameters after DHA oil intake could be the result
of interactions between gut microbiota and DHA metabolites
potentially through the enterohepatic circulation of bile salts
(Yokota et al., 2012; Sayin et al., 2013). However, our study was
not designed to test this hypothesis and further investigation on
the bile excretion analysis is required to proof or disproof this
hypothesis.
All being said, our study also had several limitations. First,
given an intervention trial period of more than 9 months
of duration during which multiple samples were collected at
different time points, some participants forgot to provide a
fecal sample on the specific sampling day. Second, the small
proportion of fecal samples might not be able to represent
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FIGURE 7 | Correlations between fecal microbiota compositions and serum lipid profiles. The non-parameteric Spearman correlation coefficient and
P-values were presented in a heatmap format. Strong and weak correlations are presented by dark and light colors, respectively. The intensity bar shows positive
and negative correlation from blue to red, respectively. ∗P < 0.1; ∗∗P < 0.05; ∗∗∗P < 0.01. F.B, ratio of Firmicutes to Bacteroidetes.
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the total fecal materials. Even after the homogenization, the
specimens could still produce large variations in the bacterial
composition and, in addition, were limited to reflect the dynamic
condition in the intestine. Third, the inclusion criteria of our
study were based on the risks of MetS, but not the obese state.
Given the lower numbers of participants with normal weight and
overweight, the statistical analyses were not optimal to compare
the direct variations among all participants.
In summary, the current study investigated the impact of
five different healthy unsaturated fatty acid oil treatments on
volunteers with risks of MetS. Results indicate that the human
gut microbiota profiles strongly relate to the body obesity states,
but also exhibit host-specificity. MUFA-rich and PUFA-rich diets
failed to shift the composition of gut microbiota at the phylum
level in a 30-day treatment period, but the populations of specific
genera can slightly alter in response to the feedings due to unclear
mechanisms. Further studies may clarify whether there is a
cause-and-effect relationship between dietary fatty types perhaps
through altered cholesterol and primary and secondary bile acid
concentration, and shifts in human gut microbiota.
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